List view / Grid view
The OlympiA trial will conduct its primary analysis early, after…
The OlympiA trial will conduct its primary analysis early, after the Independent Data Monitoring Committee found it met its primary endpoint in BRCA mutated early breast cancer patients.
AstraZenaca reveals Calquence (acalabrutinib) did not increase the proportion of…
AstraZenaca reveals Calquence (acalabrutinib) did not increase the proportion of hospitalised COVID-19 patients who remained alive and free of respiratory failure.
Priority Review has been granted for [fam-] trastuzumab deruxtecan (DS-8201)…
Priority Review has been granted for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of HER2-positive metastatic breast cancer.
The FDA has announced Orphan Drug Designation for Imfinzi (durvalumab)…
The FDA has announced Orphan Drug Designation for Imfinzi (durvalumab) to treat small cell lung cancer in combination with other therapies.
